1/ The June 2021 Edition of MDA Fellows JCWatch 📰 is now available❗️ Check out all 6️⃣ #journalclub summaries below 👇🏽 that cover GU, GI, & breast medical oncology ➕ classical hematology & SCT! #meded @MDanmolsingh @HemOncFellows @HOJournalClub @Hemoncq @MDAndersonNews
2/ First up, Dr. Ferreri presented an interesting article evaluating the potential to classify tumor microenvironments into one of four subtypes to predict response to immunotherapy ⚡️ 🔗pubmed.ncbi.nlm.nih.gov/34019806/ 
3/ Next, Dr. @FasaAgbedia presented the results of the phase 3️⃣ ASCENT trial that demonstrated ⬆️ OS and ⬆️ PFS w/ sacituzumab govitecan vs standard single agent chemotherapy in pretreated metastatic TNBC #bcsm 🔗pubmed.ncbi.nlm.nih.gov/33882206/
4/ Dr. @MDanmolsingh presented the practice-changing ✅ results of CheckMate♟ 577 evaluating the role of adjuvant nivolumab in high-risk resected esophageal/GEJ cancer patients. 🔗nejm.org/doi/full/10.10…
5/ Dr. @chijioke_nze took on the challenge of presenting an interesting #classicalhematology 🩸 trial evaluating a regimen of immunosuppresion and plasma exchange ➕upfront caplacizumab in the management of immune-mediated TTP 🔗pubmed.ncbi.nlm.nih.gov/33150928/
6/ Next, Dr. @MNakazawa8 reviewed an article evaluating the clinical effects of administering leukemia specific donor T cells 🧫 to high-risk AML/MDS patients after allo transplant 🔗pubmed.ncbi.nlm.nih.gov/33270816/
7/ And last (but certainly not least), Dr. Gordon presented the results of the 🔤06 trial evaluating the outcomes of 2L FOLFOX vs active symptom control in the management of advanced biliary tract cancer 🔗thelancet.com/journals/lanon…
@threadreaderapp unroll
• • •
Missing some Tweet in this thread? You can try to
force a refresh
